Evidence map›Paper›PMID 31315958›Full record

ArticleJournal of clinical microbiology2019

A Multicenter Study To Evaluate Ceftaroline Breakpoints: Performance in an Area with High Prevalence of Methicillin-Resistant Staphylococcus aureus Sequence Type 5 Lineage.

Ayesha Khan, Lina M Rivas, Maria Spencer, Rodrigo Martinez, Marusella Lam, Pamela Rojas, Lorena Porte, Francisco Silva, Stephanie Braun, Francisca Valdivieso and 6 more

Erratum issuedAbstract readComparative StudyEvaluation StudyMulticenter Study
In one paragraph

Article in Journal of clinical microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Evaluation ofIranian journal of microbiology · 2021
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Ayesha Khan *Center for Antimicrobial Resistance and Microbial Genomics and Division of Infectious Diseases, University of Texas Health Science Center, McGovern Medical School, Houston, Texas, USA.ORCID 0000-0002-0489-0712
Lina M Rivas *Genomics and Resistant Microbes Group, Facultad de Medicina-Clinica Alemana, Universidad del Desarrollo, Santiago, Chile.
Maria SpencerGenomics and Resistant Microbes Group, Facultad de Medicina-Clinica Alemana, Universidad del Desarrollo, Santiago, Chile.
Rodrigo MartinezGenomics and Resistant Microbes Group, Facultad de Medicina-Clinica Alemana, Universidad del Desarrollo, Santiago, Chile.
Marusella LamDepartamento de Laboratorios Clínicos, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
Pamela RojasHospital Padre Hurtado, Santiago, Chile.
Lorena PorteGenomics and Resistant Microbes Group, Facultad de Medicina-Clinica Alemana, Universidad del Desarrollo, Santiago, Chile.
Francisco SilvaHospital Clínico Universidad de Chile, Santiago, Chile.
Stephanie BraunHospital Militar, Santiago, Chile.
Francisca ValdiviesoHospital Dr. Luis Calvo Mackenna, Santiago, Chile.
Margareta Mv LhauserHospital Dipreca, Santiago, Chile.
Mónica LafourcadeClínica Santa María, Santiago, Chile.
William R MillerCenter for Antimicrobial Resistance and Microbial Genomics and Division of Infectious Diseases, University of Texas Health Science Center, McGovern Medical School, Houston, Texas, USA.
Patricia GarcíaMillennium Initiative for Collaborative Research on Bacterial Resistance (MICROB-R), Millennium Science Initiative, Santiago, Chile.
Cesar A AriasCenter for Antimicrobial Resistance and Microbial Genomics and Division of Infectious Diseases, University of Texas Health Science Center, McGovern Medical School, Houston, Texas, USA Cesar.Arias@uth.tmc.edu Jose.M.Munita@uth.tmc.edu.
Jose M MunitaCenter for Antimicrobial Resistance and Microbial Genomics and Division of Infectious Diseases, University of Texas Health Science Center, McGovern Medical School, Houston, Texas, USA Cesar.Arias@uth.tmc.edu Jose.M.Munita@uth.tmc.edu.

Funding

The LiaFSR system and antimicrobial peptide resistance in enterococciR01AI134637 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI Cesar Augusto Arias · 2018 to 2026
$3.7M
Molecular Mechanisms Of Daptomycin Resistance In EnterococciR01AI093749 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARIAS, CESAR AUGUSTO · 2011 to 2015
$1.9M
POR Program on Genomic Prediction of Antimicrobial Resistance in VREK24AI121296 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARIAS, CESAR AUGUSTO · 2016 to 2025
$1.5M
Role of YxdJK and DAK in the Enterococcal Envelope Stress ResponseK08AI135093 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI MILLER, WILLIAM R · 2018 to 2022
$929k
Molecular basis of the cefazolin inoculum effectR21AI143229 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARIAS, CESAR AUGUSTO · 2019 to 2020
$442k
Targeting Cell Membrane Adaptation in Multidrug-Resistant Enterococcus faeciumR21AI121519 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARIAS, CESAR AUGUSTO · 2016 to 2017
$226k
NIAID NIH HHS K08 AI135093NIAID NIH HHS K24 AI121296NIAID NIH HHS R01 AI093749NIAID NIH HHS R01 AI134637NIAID NIH HHS R21 AI121519NIAID NIH HHS R21 AI143229
6 · The paper itself

Abstract

Ceftaroline (CPT) is a broad-spectrum agent with potent activity against methicillin-resistant

Indexed as

Anti-Bacterial AgentsCeftarolineCephalosporinsChileCommunity-Acquired InfectionsCross InfectionHumansMethicillin-Resistant Staphylococcus aureusMicrobial Sensitivity TestsPrevalenceStaphylococcal InfectionsAnti-Bacterial AgentsCeftarolineCephalosporinsbreakpointsceftarolinedisk diffusionEtestMICMRSA

Identifiers

PMID31315958
PMCPMC6711923

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.